Relapsed or Refractory NK/T-Cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed or Refractory NK/T-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (NCT07502768) | Rong Tao | 2026-04-30 |
Track Relapsed or Refractory NK/T-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.